Mankind Pharma Valuation
Is 543904 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 543904 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 543904 (₹2612.05) is trading above our estimate of fair value (₹1413.73)
Significantly Below Fair Value: 543904 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 543904?
Key metric: As 543904 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 543904's PE Ratio? | |
|---|---|
| PE Ratio | 49.4x |
| Earnings | ₹21.15b |
| Market Cap | ₹1.02t |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.9x |
| Enterprise Value/EBITDA | 36x |
| PEG Ratio | 3.2x |
Price to Earnings Ratio vs Peers
How does 543904's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 34.9x | ||
500124 Dr. Reddy's Laboratories | 18.9x | -1.0% | ₹1.0t |
500420 Torrent Pharmaceuticals | 61.4x | 22.7% | ₹1.1t |
ZYDUSLIFE Zydus Lifesciences | 22.7x | 0.6% | ₹955.0b |
500257 Lupin | 36.6x | 16.4% | ₹944.3b |
543904 Mankind Pharma | 49.4x | 15.4% | ₹1.0t |
Price-To-Earnings vs Peers: 543904 is expensive based on its Price-To-Earnings Ratio (49.4x) compared to the peer average (34.9x).
Price to Earnings Ratio vs Industry
How does 543904's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
INDSWFTLAB Ind-Swift Laboratories | 1.6x | n/a | US$70.56m |
524652 Ind-Swift | 2x | n/a | US$13.15m |
| 2 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 543904 is expensive based on its Price-To-Earnings Ratio (49.4x) compared to the Indian Pharmaceuticals industry average (31.7x).
Price to Earnings Ratio vs Fair Ratio
What is 543904's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 49.4x |
| Fair PE Ratio | 45.8x |
Price-To-Earnings vs Fair Ratio: 543904 is expensive based on its Price-To-Earnings Ratio (49.4x) compared to the estimated Fair Price-To-Earnings Ratio (45.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ₹2,612.05 | ₹2,814.88 +7.8% | 11.9% | ₹3,300.00 | ₹2,275.00 | n/a | 16 |
| Nov ’25 | ₹2,690.55 | ₹2,469.87 -8.2% | 15.2% | ₹3,300.00 | ₹1,900.00 | n/a | 15 |
| Oct ’25 | ₹2,576.75 | ₹2,445.07 -5.1% | 14.9% | ₹3,300.00 | ₹1,900.00 | n/a | 15 |
| Sep ’25 | ₹2,488.00 | ₹2,297.57 -7.7% | 10.1% | ₹2,760.00 | ₹1,900.00 | n/a | 14 |
| Aug ’25 | ₹2,004.95 | ₹2,289.71 +14.2% | 9.5% | ₹2,650.00 | ₹1,900.00 | n/a | 14 |
| Jul ’25 | ₹2,162.15 | ₹2,302.87 +6.5% | 10.3% | ₹2,650.00 | ₹1,800.00 | n/a | 15 |
| Jun ’25 | ₹2,146.05 | ₹2,266.93 +5.6% | 9.8% | ₹2,554.00 | ₹1,800.00 | n/a | 14 |
| May ’25 | ₹2,366.00 | ₹2,199.77 -7.0% | 10.9% | ₹2,520.00 | ₹1,750.00 | n/a | 13 |
| Apr ’25 | ₹2,312.35 | ₹2,197.69 -5.0% | 10.9% | ₹2,520.00 | ₹1,750.00 | n/a | 13 |
| Mar ’25 | ₹2,147.70 | ₹2,184.17 +1.7% | 11.2% | ₹2,520.00 | ₹1,750.00 | n/a | 12 |
| Feb ’25 | ₹2,044.35 | ₹1,937.73 -5.2% | 13.0% | ₹2,300.00 | ₹1,433.00 | n/a | 11 |
| Jan ’25 | ₹1,977.65 | ₹1,859.00 -6.0% | 10.7% | ₹2,140.00 | ₹1,433.00 | n/a | 11 |
| Dec ’24 | ₹1,917.20 | ₹1,859.00 -3.0% | 10.7% | ₹2,140.00 | ₹1,433.00 | n/a | 11 |
| Nov ’24 | ₹1,744.50 | ₹1,853.73 +6.3% | 11.0% | ₹2,190.00 | ₹1,433.00 | ₹2,690.55 | 11 |
| Oct ’24 | ₹1,793.15 | ₹1,817.82 +1.4% | 12.9% | ₹2,180.00 | ₹1,433.00 | ₹2,576.75 | 11 |
| Sep ’24 | ₹1,725.45 | ₹1,838.60 +6.6% | 12.8% | ₹2,180.00 | ₹1,433.00 | ₹2,488.00 | 10 |
| Aug ’24 | ₹1,771.30 | ₹1,626.30 -8.2% | 10.0% | ₹1,875.00 | ₹1,425.00 | ₹2,004.95 | 10 |
| Jul ’24 | ₹1,706.30 | ₹1,648.67 -3.4% | 9.5% | ₹1,875.00 | ₹1,429.00 | ₹2,162.15 | 9 |
| Jun ’24 | ₹1,398.15 | ₹1,484.50 +6.2% | 3.1% | ₹1,539.00 | ₹1,429.00 | ₹2,146.05 | 4 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Venus Remedies
₹3.9b
Engages in the pharmaceutical business in India and internationally.
VENUSREM
₹294.55
7D
-0.4%
1Y
-21.5%
Vivimed Labs
₹410.4m
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.
VIVIMEDLAB
₹4.95
7D
0%
1Y
-45.9%
Granules India
₹135.5b
Manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly.
532482
₹574.50
7D
8.6%
1Y
48.3%